

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
Vice-Chair: Sonali M. Smith, MD
Executive Officer: Susan M. O'Brien, MD
Statisticians: Michael LeBlanc, PhD
..... Hongli Li, MS

Scientific Leadership

Translational Medicine: Alexey V. Danilov, MD, PhD
Radiation Oncology: Louis S. Constine, MD
Imaging: Lawrence H. Schwartz, MD
Pathology: Joo Y. Song, MD
Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
Digital Engagement: Mazyar Shadman, MD
Veterans Affairs: Helen Ma, MD
Data Coordinators: Iris Syquia
..... Gabi Herbert

Oncology Research Professionals:

CRA: Erin M. Cebula, MPH
Nurse: Molly Beth Adamek, BSN, RN
Patient Advocate: Hildy Dillon, MPH
Pharmaceutical Science: Holly O. Chan, PharmD
..... Martina Fraga, PharmD
Protocol Project Manager: Alicia Aranda
Clinical Trials Program Manager: Michelle Maxim

Time/Location

Friday, April 8, 2022 9:00 am - 12:00 pm
Room: Quinalt, Level 5

Agenda

9:00 am: Welcome - Drs. Jonathan Friedberg and Sonali Smith
9:05 - 9:50 am: **Mini-symposium: Novel diagnostic and therapeutic approaches to B-cell malignancies**
Ultrasensitive Duplex Sequencing for Applications in Hematologic Malignancies
Jesse Salk MD, PhD
CEO, CSO, Founder
TwinStrand Biosciences Inc.
Clinical Assistant Professor
University of Washington, Division of Medical Oncology

Targeting CD20 with novel CAR-T constructs

Brian Till, MD
Associate Professor
University of Washington, Division of Medical Oncology
Fred Hutchinson Cancer Research Center

9:50 - 10:30 am: New Concepts

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Re-lapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Dr. Hess.

S2207, "Randomized phase II study of the addition of COO (cell-of-origin)-directed therapeutic agents to ta-fasitamab-based therapy in non-transplant-eligible patients with relapsed/refractory diffuse large B-cell lymphoma." Drs. Persky, Amengual and Reagan

Alliance Mantle Cell lymphoma - Dr. Phillips

COG Early stage Hodgkin lymphoma - Dr. Hu

10:30 - 10:50 am: ASH Review - New treatment approaches to newly diagnosed and relapsed diffuse large B-cell lymphoma - Dr. Kamdar

10:50 - 11:50 am: Ongoing Studies

S1826: Dr. Herrera

S1918: Dr. Brem

S1608: Dr. Barr

A051301: Dr. Stiff

A051902: Dr. Amengual

ANHL1931: Dr. Kamdar

EA4151: Dr. Till

E4412: Dr. Amengual

EA4181: Dr. Spurgeon

A051701: Dr. Vallurupalli

S1925 (CLL): Dr. Stephens

11:50 am - 12:00 pm: Other Business/Concluding Remarks

Lymphoma Committee

Active Studies

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera and Friedberg. Activated: 7/19/19.

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Temporarily Closed as of 02/09/22

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

CTSU/A051301, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Drs. Andreadis, Fenske, Leonard, Devine, Shea, Hsi, Kelley, and Richards. SWOG Champion: Dr. Stiff. Activated: 7/6/16.

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Drs. Fenske, Till, Blum, Lazarus, Scott, and Kostakoglu. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma. Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." SWOG Champion: Dr. Kamdar. SWOG Champion: Dr. Manali. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Neha Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

Open Leukemia Studies

S1925, A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study. Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Re-lapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

A041702, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Veneto-clax and Obinutuzumab in Untreated Older Patients (\geq 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Woyach. SWOG Champion: Dr. Hill. Activated: 1/4/19.

Open Rare Cancers Study

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)." Drs. Chen, Flaherty, Conley, et al. Activated: 8/12/15.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/27/2021.

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	1	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	8	-	8	10
Cancer Research Consortium of West Michigan NCORP	3	8	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	8	15	-	1	-	-	15	-
Columbia University Minority Underserved NCORP	-	1	2	-	-	1	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	3	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	11	-
Georgia Cares Minority Underserved NCORP	-	2	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	16	-	-	-	-	-	-
Henry Ford Hospital	-	6	-	-	2	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	10	-	-	-	11	-	5
King Faisal Specialist Hospital and Research Centre	-	-	-	4	-	-	-	-
Loyola University Medical Center	-	5	-	-	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	2	13	-	-	3	-	2	-
Michigan Cancer Research Consortium NCORP	1	2	-	-	-	-	-	-
Moffitt Cancer Center	-	13	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	10	-	-	-	-	2	-

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	1	-	-
Northwell Health NCORP	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	2	-	-	2	-	4	5
Pacific Cancer Research Consortium NCORP	-	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	4	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	8	-	-	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	7	-	-	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	11	-	-	3	7	5	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	6	-	-	-	-	1	1
University of Colorado Cancer Center LAPS	-	2	-	1	-	-	-	-
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-
University of Rochester LAPS	13	27	-	3	11	-	8	14
University of Texas Health Science Center at San Antonio	-	8	-	-	-	-	9	-
University of Texas MD Anderson Cancer Center LAPS	3	14	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	-	-	12	10
Upstate Carolina Consortium Community Oncology Research Program	1	6	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	3	-	1	-	-	1	4
Wisconsin NCI Community Oncology Research Program	-	6	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	4	-	-	-	-	2	-
ALLIANCE	15	85	9	-	-	-	-	-
CCTG	-	2	-	-	-	-	-	-
COG	-	227	-	-	-	-	-	-
ECOG-ACRIN	5	57	4	-	-	-	-	-
NRG	11	38	2	-	-	-	-	-
Total	72	669	19	12	34	20	86	51

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	1	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	8	-	8	10
Cancer Research Consortium of West Michigan NCORP	3	8	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	8	15	-	1	-	-	15	-
Columbia University Minority Underserved NCORP	-	1	2	-	-	1	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	3	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	11	-
Georgia Cares Minority Underserved NCORP	-	2	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	16	-	-	-	-	-	-
Henry Ford Hospital	-	6	-	-	2	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	10	-	-	-	11	-	5
King Faisal Specialist Hospital and Research Centre	-	-	-	4	-	-	-	-
Loyola University Medical Center	-	5	-	-	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	2	13	-	-	3	-	2	-
Michigan Cancer Research Consortium NCORP	1	2	-	-	-	-	-	-
Moffitt Cancer Center	-	13	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	10	-	-	-	-	2	-

Lymphoma Committee

Accrual from trial opening through 12/31/2021 by Institution and Study

	S1608	S1826	S1918	A051301	A051701	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	1	-	-	-	1	-	-
Northwell Health NCORP	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	2	-	-	2	-	4	5
Pacific Cancer Research Consortium NCORP	-	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	4	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	8	-	-	4	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	7	-	-	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	11	-	-	3	7	5	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	6	-	-	-	-	1	1
University of Colorado Cancer Center LAPS	-	2	-	1	-	-	-	-
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-
University of Rochester LAPS	13	27	-	3	11	-	8	14
University of Texas Health Science Center at San Antonio	-	8	-	-	-	-	9	-
University of Texas MD Anderson Cancer Center LAPS	3	14	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	-	-	12	10
Upstate Carolina Consortium Community Oncology Research Program	1	6	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	3	-	1	-	-	1	4
Wisconsin NCI Community Oncology Research Program	-	6	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	4	-	-	-	-	2	-
ALLIANCE	15	85	9	-	-	-	-	-
CCTG	-	2	-	-	-	-	-	-
COG	-	227	-	-	-	-	-	-
ECOG-ACRIN	5	57	4	-	-	-	-	-
NRG	11	38	2	-	-	-	-	-
Total	72	669	19	12	34	20	86	51